Skip to main content
OpenTrials
Completed

NCT Number: NCT00949832

Vitamin D and Genetics in Nutritional Rickets

The purpose of this study is:

1. To compare the response of rickets to calcium with and without vitamin D. 2. To assess whether vitamin D increases calcium absorption in calcium deficiency rickets. 3. To compare the response of children with and without rickets to orally administered vitamin D3 and vitamin D2 4. To identify mutations that influence calcium and vitamin D metabolism among families of children with rickets in Nigeria and Bangladesh. 5. To assess the functional status of the 25-hydroxylase enzyme in families possessing a 25-hydroxylase mutation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 month–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Jos University Teaching Hospital

Jos, Plateau State, 930001, Nigeria

About this study

Previous studies of Nigerian children with rickets demonstrated the superiority of calcium over vitamin D in producing healing. It is not known whether the addition of vitamin D to calcium will produce a better response to treatment than calcium alone in Nigerian children. A previous study suggested the possibility that vitamin D may augment the effect of calcium. We will compare the response of rickets to calcium with and without vitamin D. In addition, very little human data clearly demonstrates the effect of supplemental vitamin D on calcium absorption. We will assess whether oral vitamin D increases the already high calcium absorption even further.

Recent published data indicate that the increase in serum 25-hydroxyvitamin D may be more sustained with vitamin D3 than with vitamin D2. We will compare the response of Nigerian children with and without rickets to orally administered vitamin D3 and vitamin D2.

Because nutritional rickets tends to run in families, we will also examine amplified DNA for evidence of mutations that influence calcium and vitamin D metabolism among families of children with rickets in Nigeria and Bangladesh. Families possessing a recently identified 25-hydroxylase mutation will be given oral vitamin D2 and vitamin D3 to determine the functional status of the 25-hydroxylase enzyme.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical features of rickets
  • Active rickets on X-ray

Exclusion criteria

  • Treatment with calcium or vitamin D in preceding 30 days

Treatment and study plan

Vitamin D + Calcium

Dietary Supplement

Vitamin D 50,000 IU orally once monthly for 6 months; Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months

Other names: ergocalciferol

Calcium

Dietary Supplement

Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months; Vitamin B complex (used as placebo) 1 tablet monthly for 6 months

Other names: limestone

Vitamin D2

Dietary Supplement

50,000 IU given orally once

Other names: ergocalciferol

Vitamin D3

Dietary Supplement

Vitamin D3 50,000 IU given orally once

Other names: cholecalciferol

Primary outcomes

  1. XR healing of rickets

    Time frame: 6 months

Secondary outcomes

  1. Alkaline phosphatase

    Time frame: 6 months

  2. Serum calcium

    Time frame: 6 months

  3. 25-hydroxyvitamin D

    Time frame: 6 months

  4. 1,25-dihydroxyvitamin D

    Time frame: 2 weeks

  5. Calcium absorption

    Time frame: 1 week

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Collaborators

  • Jos University Teaching Hospital

Registry information

Important dates

Study start
2004
Primary completion
2007
Study completion
2007
First posted
Jul 30, 2009
Registry last updated
Jul 4, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.